• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Sep 1, 1997; 100(5): 1282–1293.
PMCID: PMC508306

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Abstract

The treatment of advanced ovarian cancer with taxol is hindered by the development of drug resistance. The cellular target for taxol is the microtubule that is stabilized by the drug. Taxol preferentially binds to the beta subunit of tubulin of which there are six distinct isotypes in mammalian cells. We have used highly specific oligonucleotides and polymerase chain reaction to analyze expression of all six beta-tubulin genes. Human lung cancer cells (A549) were selected in 12 and 24 nM taxol resulting in cell lines that were 9- and 17-fold resistant, respectively. These cells displayed an altered ratio of classes I, II, III, and IVa beta-tubulin isotypes. Ovarian tumors, seven untreated primary and four taxol- resistant tumor-bearing ascites, displayed significant increases (P < 0.005) in classes I (3.6-fold), III (4.4-fold), and IVa (7.6-fold) isotypes in the taxol-resistant samples as compared with untreated primary ovarian tumors. The increased expression appears to be related to the resistance phenotype, as the basal levels of the class III and IVa isotypes in the untreated tumors were extremely low. This is the first report of altered expression of specific beta-tubulin genes in taxol-resistant ovarian tumors and we propose that the latter may play a role in clinical resistance to taxol.

Full Text

The Full Text of this article is available as a PDF (386K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. [PubMed]
  • Cannistra SA. Cancer of the ovary. N Engl J Med. 1993 Nov 18;329(21):1550–1559. [PubMed]
  • Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer. 1993 Jan 15;71(2 Suppl):644–649. [PubMed]
  • McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. [PubMed]
  • Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797–1805. [PubMed]
  • Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993 Mar 3;85(5):384–388. [PubMed]
  • Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;(15):55–61. [PubMed]
  • Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325–2327. [PubMed]
  • Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561–1565. [PMC free article] [PubMed]
  • Rao S, Orr GA, Chaudhary AG, Kingston DG, Horwitz SB. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J Biol Chem. 1995 Sep 1;270(35):20235–20238. [PubMed]
  • Cowan NJ, Dudley L. Tubulin isotypes and the multigene tubulin families. Int Rev Cytol. 1983;85:147–173. [PubMed]
  • Sullivan KF, Cleveland DW. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4327–4331. [PMC free article] [PubMed]
  • Sullivan KF. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol. 1988;4:687–716. [PubMed]
  • Burgoyne RD, Cambray-Deakin MA, Lewis SA, Sarkar S, Cowan NJ. Differential distribution of beta-tubulin isotypes in cerebellum. EMBO J. 1988 Aug;7(8):2311–2319. [PMC free article] [PubMed]
  • Wang D, Villasante A, Lewis SA, Cowan NJ. The mammalian beta-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype. J Cell Biol. 1986 Nov;103(5):1903–1910. [PMC free article] [PubMed]
  • Panda D, Miller HP, Banerjee A, Ludueña RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11358–11362. [PMC free article] [PubMed]
  • Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry. 1995 Feb 21;34(7):2203–2211. [PubMed]
  • Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552–9556. [PMC free article] [PubMed]
  • Lu Q, Luduena RF. Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct. 1993 Jun;18(3):173–182. [PubMed]
  • Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem. 1995 Dec 29;270(52):31269–31275. [PubMed]
  • Roy SN, Horwitz SB. A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res. 1985 Aug;45(8):3856–3863. [PubMed]
  • Greenberger LM, Lothstein L, Williams SS, Horwitz SB. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci U S A. 1988 Jun;85(11):3762–3766. [PMC free article] [PubMed]
  • Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. [PMC free article] [PubMed]
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. [PubMed]
  • Kuo DY, Mallick S, Shen HJ, DeVictoria C, Jones J, Fields AL, Goldberg GL, Runowicz CD, Horwitz SB. Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry. Clin Cancer Res. 1996 Dec;2(12):1981–1992. [PubMed]
  • Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160–7164. [PMC free article] [PubMed]
  • Gilbert J, Norris MD, Haber M, Kavallaris M, Marshall GM, Stewart BW. Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction. Mol Cell Probes. 1993 Jun;7(3):227–234. [PubMed]
  • Jaffrézou JP, Dumontet C, Derry WB, Durán G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sikic BI. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res. 1995;7(10-11):517–527. [PubMed]
  • Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994 Oct 1;54(19):5036–5040. [PubMed]
  • Chomczynski P, Qasba PK. Alkaline transfer of DNA to plastic membrane. Biochem Biophys Res Commun. 1984 Jul 18;122(1):340–344. [PubMed]
  • Khandjian EW, Méric C. A procedure for Northern blot analysis of native RNA. Anal Biochem. 1986 Nov 15;159(1):227–232. [PubMed]
  • Cabral F, Barlow SB. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J. 1989 Mar;3(5):1593–1599. [PubMed]
  • Cabral FR, Brady RC, Schibler MJ. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann N Y Acad Sci. 1986;466:745–756. [PubMed]
  • Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M, Saijo N. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res. 1994 Mar;85(3):290–297. [PubMed]
  • Laferrière NB, Brown DL. Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Biochem Cell Biol. 1995 Sep-Oct;73(9-10):687–694. [PubMed]
  • Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem. 1991 Feb 25;266(6):3987–3994. [PubMed]
  • Weinstein B, Solomon F. Phenotypic consequences of tubulin overproduction in Saccharomyces cerevisiae: differences between alpha-tubulin and beta-tubulin. Mol Cell Biol. 1990 Oct;10(10):5295–5304. [PMC free article] [PubMed]
  • Burke D, Gasdaska P, Hartwell L. Dominant effects of tubulin overexpression in Saccharomyces cerevisiae. Mol Cell Biol. 1989 Mar;9(3):1049–1059. [PMC free article] [PubMed]
  • Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996 Jun 1;56(11):2584–2589. [PubMed]
  • Murdoch WJ. Ovarian surface epithelium, ovulation and carcinogenesis. Biol Rev Camb Philos Soc. 1996 Nov;71(4):529–543. [PubMed]
  • Lewis SA, Gilmartin ME, Hall JL, Cowan NJ. Three expressed sequences within the human beta-tubulin multigene family each define a distinct isotype. J Mol Biol. 1985 Mar 5;182(1):11–20. [PubMed]
  • Lewis SA, Gu W, Cowan NJ. Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell. 1987 May 22;49(4):539–548. [PubMed]
  • Lewis SA, Lee MG, Cowan NJ. Five mouse tubulin isotypes and their regulated expression during development. J Cell Biol. 1985 Sep;101(3):852–861. [PMC free article] [PubMed]
  • Ludueña RF. Are tubulin isotypes functionally significant. Mol Biol Cell. 1993 May;4(5):445–457. [PMC free article] [PubMed]
  • Alexander JE, Hunt DF, Lee MK, Shabanowitz J, Michel H, Berlin SC, MacDonald TL, Sundberg RJ, Rebhun LI, Frankfurter A. Characterization of posttranslational modifications in neuron-specific class III beta-tubulin by mass spectrometry. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4685–4689. [PMC free article] [PubMed]
  • Mary J, Redeker V, Le Caer JP, Promé JC, Rossier J. Class I and IVa beta-tubulin isotypes expressed in adult mouse brain are glutamylated. FEBS Lett. 1994 Oct 10;353(1):89–94. [PubMed]
  • Rüdiger M, Plessman U, Klöppel KD, Wehland J, Weber K. Class II tubulin, the major brain beta tubulin isotype is polyglutamylated on glutamic acid residue 435. FEBS Lett. 1992 Aug 10;308(1):101–105. [PubMed]
  • Khan IA, Ludueña RF. Phosphorylation of beta III-tubulin. Biochemistry. 1996 Mar 26;35(12):3704–3711. [PubMed]
  • Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 1992 Oct 7;84(19):1486–1491. [PubMed]
  • Kavallaris M, Leary JA, Barrett JA, Friedlander ML. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett. 1996 Apr 19;102(1-2):7–16. [PubMed]
  • Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Bénard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res. 1989 Sep 15;49(18):5062–5065. [PubMed]
  • Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol. 1985 Mar;3(3):311–315. [PubMed]
  • McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. [PubMed]
  • Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. [PMC free article] [PubMed]
  • Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994 Nov 15;54(22):5902–5910. [PubMed]
  • van der Zee AG, Hollema HH, de Bruijn HW, Willemse PH, Boonstra H, Mulder NH, Aalders JG, de Vries EG. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol. 1995 Aug;58(2):165–178. [PubMed]
  • Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry. 1997 Mar 25;36(12):3554–3562. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...